Serum Lactate Dehydrogenase (LDH) as a Tumor Marker in Ewing's Sarcoma
Authors:
Open Access
- 1 December 1988
- journal article
- research article
- Published by SAGE Publications in Tumori Journal
- Vol. 74 (6) , 649-655
Abstract
The pretreatment serum lactic acid dehydrogenase (LDH) level of 246 patients with Ewing's sarcoma of bone (47 metastatic and 199 localized at presentation) was examined to evaluate the use of LDH as a tumor marker. The percentage of patients with increased serum LDH levels was significantly higher in the metastatic group than in the group of patients with localized disease (83 % vs 41 %; p < 0.01). In the latter group the relapse rate after treatment with combined therapy was significantly higher in patients with an elevated serum LDH at admission than in those with normal serum levels (68.2 % vs 39.3 %; p < 0.01). After local treatment, in 73 out of 82 patients with an elevated serum LDH at admission the enzyme level normalized whereas in 9 it fell but never reached a normal value. The rate of relapse in these two groups was respectively 64 % and 100 %. The value of serum LDH at the time of recurrence, determined in 62 patients, was elevated in 50 (80.7 %). These data demonstrate that in Ewing's sarcoma of bone pretreatment serum LDH levels have a definitive value in establishing the prognosis and could also be used in evaluating the response to therapy. A persistent elevated value of serum LDH, or an increasing value after a transient normalization, is usually followed by relapse.Keywords
This publication has 14 references indexed in Scilit:
- Lactase dehydrogenase as a tumor marker for recurrent disease in Ewing's sarcomaCancer, 1987
- Die kooperative Ewing-Sarkom-Studie CESS 81 der GPO - Analyse nach 4 Jahren*+(*Klinische Padiatrie, 1985
- Localized Ewing's sarcoma of bone: Ten years' experience at the Istituto Ortopedico Rizzoli in 124 cases treated with multimodal therapyEuropean Journal of Cancer and Clinical Oncology, 1985
- Elevation of serum lactic dehydrogenase levels as an early marker of occult malignant lymphomaCancer, 1984
- The treatment of localized Ewing's sarcoma: The experience at the istituto ortopedico rizzoli in 163 cases treated with and without adjuvant chemotherapyCancer, 1982
- Ewing's sarcoma: Ten-year experience with adjuvant chemotherapyCancer, 1981
- Biochemical Markers in Lymphoid MalignancyNew England Journal of Medicine, 1980
- Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcomaCancer, 1980
- Pretreatment Serum Lactate Dehydrogenase Predicting Metastatic Spread in Ewing's SarcomaAnnals of Internal Medicine, 1975
- Lactic Dehydrogenase Activity in Blood.Experimental Biology and Medicine, 1955